McKesson Corporation (MCK) - Stock Analysis
Last updated: Mar 8, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
McKesson shows strong short-term momentum with a 10% revenue increase and earnings beat in Q2 FY2026, supported by strategic specialty pharma growth and positive analyst upgrades (Zacks Strong Buy). Technicals confirm ~11.6% gain over 21 days, well above key moving averages, indicating near-term price appreciation potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Massive scale ⢠Thin margins ⢠Negative equity McKesson combines very large scale and consistent free cash flow with razorâthin operating margins, subâ1 current ratio and negative book equity, creating a cashâgenerative but liquidity/solvencyârisk profile to monitor.
Price Behavior
Key Price Behavior Insights: ⢠Late surge ⢠Quick pullback ⢠Elevated volatility Support Level: $915.24; $933â$947 Resistance Level: $995.69 McKesson rallied into a late surge last month up to $995.69 then quickly pulled back to $919.26, trading ~3.6% below its last-month 21-day SMA (~$953) â signaling short-term volatility and a possible distribution rather than trend continuation.
Sentiment & News
Key News Insights: ⢠Robust results ⢠Raised guidance ⢠CFO transition McKesson reported strong Q3 results and raised FY26 guidance, drawing heavy investor and institutional activity amid active portfolio reshuffling and a nearâterm CFO transition.
AI Summary
McKesson is morphing from a lowâmargin distributor into a cash-rich, specialtyâandâservices platform where FCF and capital redeploymentânot margin expansionâwill determine returns; investors should require near-term evidence of sustained oncology/specialty revenue mix, stable workingâcapital metrics, and disciplined buybacks/M&A before committing.
Description
McKesson Corporation is a healthcare services and distribution company operating in the United States and select international markets. Its operations span pharmaceutical distribution, medical-surgical supply logistics, and a range of technology, consulting and outsourcing services for pharmacies, specialty practices and institutional customers, while a dedicated business supports biopharma partners and supply-chain needs. The company was founded in 1833 and is headquartered in Irving, Texas.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 10 | Nov 17 | MCK | McKesson Corporation | McKesson shows strong short-term momentum with a 10% revenue increase and earnings beat in Q2 FY2026, supported by strategic specialty pharma growth and positive analyst upgrades (Zacks Strong Buy). Technicals confirm ~11.6% gain over 21 days, well above key moving averages, indicating near-term price appreciation potential. | Closed | -0.5% |